Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial
Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER…
Lance A. Slatton Named Brand Ambassador for BareFoot Sandal, Championing Mobility, Confidence, and Independence
CEO.CA’s Inside the Boardroom: Goldinxs Targeting Major Discovery Near Artemis Gold’s Blackwater Mine
CEO.CA’s Inside the Boardroom: No Approved Drug Does What Marvel’s Lead Candidate Can Do for Autism
DFW Lonestar Rentals Surpasses 600 Vehicles And Expands Fleet Inventory
Uniserve Provides Vancouver Data Centre Update and Advances Canadian Digital Infrastructure Strategy